DarioHealth (NASDAQ:DRIO) Stock Price Crosses Above Fifty Day Moving Average – Should You Sell?

DarioHealth Corp. (NASDAQ:DRIO)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $7.42 and traded as high as $7.49. DarioHealth shares last traded at $7.22, with a volume of 2,316 shares.

Analysts Set New Price Targets

DRIO has been the subject of several recent research reports. Stifel Nicolaus restated a “buy” rating and set a $10.00 target price on shares of DarioHealth in a research report on Thursday, May 14th. TD Cowen reiterated a “hold” rating and issued a $11.00 price target on shares of DarioHealth in a research report on Wednesday, May 13th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, DarioHealth has an average rating of “Hold” and an average target price of $10.50.

DarioHealth Stock Performance

The firm has a market capitalization of $52.78 million, a PE ratio of -0.81 and a beta of 1.09. The company has a debt-to-equity ratio of 0.50, a quick ratio of 2.62 and a current ratio of 3.07. The business’s fifty day simple moving average is $7.42 and its 200-day simple moving average is $9.03.

Institutional Investors Weigh In On DarioHealth

Several large investors have recently made changes to their positions in the company. Kestra Advisory Services LLC purchased a new stake in shares of DarioHealth in the fourth quarter worth about $35,000. Geode Capital Management LLC grew its holdings in DarioHealth by 167.9% during the 4th quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after buying an additional 31,063 shares in the last quarter. Finally, XTX Topco Ltd increased its stake in DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock worth $42,000 after acquiring an additional 43,513 shares during the last quarter. 33.39% of the stock is owned by institutional investors.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.